Scarica l'app Stockscreener
48.78
1.90%
0.91
Dopo l'orario di chiusura:
48.76
-0.02
-0.04%
Cidara Therapeutics Inc Borsa (CDTX) Ultime notizie
(CDTX) Proactive Strategies - news.stocktradersdaily.com
Cidara Therapeutics (CDTX) Receives Buy Rating from HC Wainwrigh - GuruFocus
H.C. Wainwright assumes coverage on Cidara stock with buy rating By Investing.com - Investing.com UK
H.C. Wainwright Initiates Coverage on Cidara Therapeutics (CDTX) with Strong Outlook | CDTX Stock News - GuruFocus
Cidara Therapeutics (NASDAQ:CDTX) Given Overweight Rating at Cantor Fitzgerald - Defense World
Cidara Therapeutics (CDTX) Reiterates Overweight Rating by Canto - GuruFocus
(CDTX) Investment Analysis - news.stocktradersdaily.com
Millennium Management LLC Raises Stock Holdings in Cidara Therapeutics, Inc. (NASDAQ:CDTX) - Defense World
Cidara Therapeutics stock maintains strong rating at Citizens JMP By Investing.com - Investing.com Canada
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $36.00 at Needham & Company LLC - Defense World
Insider Buying: Chrysa Mineo Acquires Shares of Cidara Therapeutics Inc (CDTX) - GuruFocus
Needham raises Cidara Therapeutics stock price target to $36 - Investing.com
Cidara Therapeutics (CDTX) Price Target Raised by Needham | CDTX Stock News - GuruFocus
Cidara Therapeutics (NASDAQ:CDTX) Given Market Outperform Rating at JMP Securities - Defense World
Cidara Therapeutics (CDTX) Maintains Market Outperform Rating | CDTX Stock News - GuruFocus
12,714 Shares in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Purchased by Jane Street Group LLC - Defense World
Northern Trust Corp Has $913,000 Stock Position in Cidara Therapeutics, Inc. (NASDAQ:CDTX) - Defense World
Cidara Therapeutics Stock (CDTX): A Notable Contender in Antivirals - Value The Markets
Cidara Therapeutics (NASDAQ:CDTX) Given “Market Outperform” Rating at JMP Securities - Defense World
JMP Securities Reiterates Market Outperform Rating for Cidara Therapeutics (CDTX) | CDTX Stock News - GuruFocus
Cidara stock target holds at $47 by JMP on trial confidence - Investing.com Canada
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Buy” from Analysts - Defense World
(CDTX) On The My Stocks Page - news.stocktradersdaily.com
Cidara Therapeutics: All Stars Aligning In Favor Of CD388 (NASDAQ:CDTX) - Seeking Alpha
Royal Bank of Canada Increases Cidara Therapeutics (NASDAQ:CDTX) Price Target to $35.00 - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Earns Buy Rating from Needham & Company LLC - Defense World
Analysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Merus (MRUS) - The Globe and Mail
Cidara Therapeutics (CDTX) Receives Price Target Upgrade from RB - GuruFocus
Cidara Therapeutics (CDTX) Receives Price Target Upgrade from RBC Capital | CDTX Stock News - GuruFocus
RBC Capital Ups Price Target for Cidara Therapeutics (CDTX) Amid Optimism | CDTX Stock News - GuruFocus
Cidara Therapeutics (CDTX): Analyst Reiterates Buy Rating | CDTX Stock News - GuruFocus
RBC Raises Price Target on Cidara Therapeutics to $35 From $31, Keeps Outperform, Speculative Risk - marketscreener.com
Transcript : Cidara Therapeutics, Inc.Special Call - marketscreener.com
Seasonal Influenza Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis - Barchart.com
Seasonal Influenza Market to Reach New Heights in Growth by 2034, - openPR.com
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
CDTX Stock Price and Chart — NASDAQ:CDTX - TradingView
When (CDTX) Moves Investors should Listen - news.stocktradersdaily.com
Cidara Therapeutics (CDTX) Target Price Raised by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised to $50 by Guggenh - GuruFocus
Cidara Therapeutics (CDTX) Target Price Raised to $50 by Guggenheim | CDTX Stock News - GuruFocus
Cidara Therapeutics price target raised to $50 from $35 at Guggenheim - TipRanks
Cidara Therapeutics to Host Virtual R&D Day to Discuss - GlobeNewswire
Revolutionary Once-Per-Year Universal Flu Prevention: Cidara Unveils Phase 2b Trial Updates at R&D Day - Stock Titan
Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025 - The Manila Times
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Cidara Therapeutics’ CD388 Progress and Challenges Highlighted in Earnings Call - MSN
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $35.00 - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Expected to Rise, JMP Securities Analyst Says - Defense World
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Guggenheim Raises Price Target for Cidara Therapeutics (CDTX) to $35.00 | CDTX Stock News - GuruFocus
StockNews.com Upgrades Cidara Therapeutics (NASDAQ:CDTX) to Sell - Defense World
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):